肝癌患者血清sCD40/sCD40L的表达水平及与预后的关系  

Expression of serum sCD40/sCD40L and its relationship with prognosis of patients with liver cancer

作　　者：郭小梅[1] 刘云华[1] 李玲霞[1] GUO Xiaomei;LIU Yunhua;LI Lingxia(The First People’s Hospital of Tianmen City,Hubei,Tianmen 431700,China)

机构地区：[1]湖北省天门市第一人民医院,431700

出　　处：《河北医药》2019年第9期1359-1362,共4页Hebei Medical Journal

基　　金：湖北省自然科学基金项目(编号:2015CFB117)

摘　　要：目的研究肝癌患者血清可溶性CD40(sCD40)和可溶性CD40配体(sCD40L)的表达水平及与预后的关系。方法选择2010年1月至2013年2月诊治的62例肝癌患者为病例组,同时期体检健康者50例为对照组。采用ELISA法检测2组血清sCD40和sCD40L水平,分析血清sCD40和sCD40L水平与肝癌患者临床病理特征的关系,分析血清sCD40和sCD40L水平与肝癌患者死亡和生存的关系。结果病例组血清sCD40和sCD40L水平显著高于对照组(P<0.05);血清sCD40和sCD40L水平与肝癌患者淋巴结转移和TNM分期有关(P<0.05),而与肿瘤分化程度、肿瘤直径无关(P>0.05);62例肝癌患者术后均随访5年,存活25例,死亡37例,总生存率40.32%,死亡组患者血清sCD40和sCD40L水平均显著高于存活组(P<0.05);sCD40高水平组患者5年生存率(35.48%)显著低于sCD40低水平组患者5年生存率(83.87%)(P<0.05);sCD40L高水平组患者5年生存率(45.16%)显著低于sCD40L低水平组患者5年生存率(74.19%)(P<0.05)。结论肝癌患者血清sCD40和sCD40L水平明显升高,其水平越高,患者病情越严重,死亡风险越高,提示血清sCD40和sCD40L升高与肝癌患者不良预后有关,可用于临床评估肝癌预后。Objective To investigate the expression of soluble CD40(sCD40),CD40 ligand(sCD40 L) and its relationship with prognosis of patients with liver cancer.Methods Sixty-two patients with liver cancer who were diagnosed and treated in our hospital from January 2010 to February 2013 were enrolled in observation group, at the same time, 50 healthy subjects who underwent physical examination were enrolled as control group. ELISA was used to detect the serum levels of sCD40 and sCD40 L of all subjects. Moreover, the relationship between the levels of sCD40. sCD40 L and clinicopathological characteristics of the patients was analyzed. In addition, the relationship between the levels of sCD40. sCD40 L and death, survival of the patients was analyzed.Results The serum levels of sCD40 and sCD40 L in observation group were significantly higher than those in control group(P<0.05), which were correlated with lymph node metastasis and TNM staging,however,which were not related to the degree of tumor differentiation and tumor diameter(P>0.05).After 5-year follow up in 62 patients with liver cancer after operation,25 cases were survived and 37 cases died, with the overall survival rate being 40.32%. The serum levels of sCD40 and sCD40 L in death group were significantly higher than those in survival group(P<0.05). Moreover, the 5-year survival rate of the patients with higher levels of sCD40(35.48%) was significantly lower than that of patients with lower levels of sCD40(83.87%)(P<0.05). The 5-year survival rate of the patients with higher levels of sCD40 L(45.16%) was significantly lower than that of patients with lower levels of sCD40 L(74.19%)(P<0.05).Conclusion The serum levels of sCD40 and sCD40 L of patients with liver cancer are increased significantly. The risk of death increases with the increase of the levels. The increase of the levels is associated with poor prognosis of patients, which can be used to evaluate the prognosis of patients with liver cancer in clinical practice.

关 键 词：肝癌 可溶性CD40 可溶性CD40配体 病理特征 5年生存率 

分 类 号：R735.7[医药卫生—肿瘤]